{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:13:18Z","timestamp":1761520398384,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA062203"],"award-info":[{"award-number":["P30CA062203"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clcc.2023.11.001","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T12:06:47Z","timestamp":1701086807000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase 1 Study of Cabozantinib and Trifluridine\/Tipiracil in Metastatic Colorectal Adenocarcinoma"],"prefix":"10.1016","volume":"23","author":[{"given":"Farshid","family":"Dayyani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Balangue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Valerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Zell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May T.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2023.11.001_bib0001","unstructured":"Cancer stat facts\u2014colorectal cancer. 2022. Accessed March 1, 2023. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html"},{"issue":"14","key":"10.1016\/j.clcc.2023.11.001_bib0002","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/tipiracil: a review in metastatic colorectal cancer","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.clcc.2023.11.001_bib0003","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"NEJM New England J Med"},{"issue":"3","key":"10.1016\/j.clcc.2023.11.001_bib0004","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2023.11.001_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.4","article-title":"Trifluridine\/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study","volume":"41","author":"Tabernero","year":"2023","journal-title":"JCO J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2023.11.001_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.clcc.2023.11.001_bib0007","first-page":"325","article-title":"Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?","volume":"10","author":"Inno","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2023.11.001_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/030089161209800115","article-title":"Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival","volume":"98","author":"Liu","year":"2012","journal-title":"Tumori"},{"issue":"12","key":"10.1016\/j.clcc.2023.11.001_bib0009","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.3748\/wjg.v21.i12.3706","article-title":"Prognostic value of c-Met in colorectal cancer: a meta-analysis","volume":"21","author":"Liu","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clcc.2023.11.001_bib0010","first-page":"165","article-title":"c-MET overexpression in colorectal cancer: a poor prognostic factor for survival","volume":"17","author":"Lee","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"27","key":"10.1016\/j.clcc.2023.11.001_bib0011","doi-asserted-by":"crossref","first-page":"23281","DOI":"10.18632\/oncotarget.3962","article-title":"AXL is an oncotarget in human colorectal cancer","volume":"6","author":"Martinelli","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.clcc.2023.11.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179979","article-title":"The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer","volume":"12","author":"Uribe","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2023.11.001_bib0013","doi-asserted-by":"crossref","first-page":"viii30","DOI":"10.1093\/annonc\/mdy269.094","article-title":"AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)","volume":"29","author":"Cardone","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2023.11.001_bib0014","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2023.11.001_bib0015","unstructured":"Cancer Institute N. Common terminology criteria for adverse events (CTCAE) v5.0; 2017. Accessed January 3, 2021. Available at: https:\/\/www.meddra.org\/"},{"key":"10.1016\/j.clcc.2023.11.001_bib0016","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014update and clarification: from the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2023.11.001_bib0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/PO.20.00379","article-title":"Designing dose-finding phase I clinical trials: top 10 questions that should be discussed with your statistician","volume":"5","author":"Lee","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2023.11.001_bib0018","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10637-016-0376-1","article-title":"A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer","volume":"34","author":"Zhen","year":"2016","journal-title":"Invest New Drugs"},{"issue":"21","key":"10.1016\/j.clcc.2023.11.001_bib0019","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.clcc.2023.11.001_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.650098","article-title":"Peritoneal metastases from colorectal cancer: defining and addressing the challenges","volume":"11","author":"Kranenburg","year":"2021","journal-title":"Front Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282300107X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153300282300107X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:09:30Z","timestamp":1761520170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153300282300107X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S153300282300107X"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2023.11.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Study of Cabozantinib and Trifluridine\/Tipiracil in Metastatic Colorectal Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2023.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}